Navigation Links
UPDATE: China PharmaHub Corp. Introduces a 'Magic Bullet' Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
Date:8/26/2010

BOSTON, Aug 26 /PRNewswire-FirstCall/ -- China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics (OTC Bulletin Board: WRLC) which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver. The Agreement gives PharmaHub the exclusive right to market in China, Hong Kong, Taiwan and Macau ("Greater China Region"), Singapore, Malaysia, and Bangladesh this innovative liver cancer treatment which is similar to a FDA-approved liver cancer therapy.

PharmaHub is a global pharmaceutical HUB that specializes in the identification, licensing, development and commercialization of pharmaceutical and healthcare products and technologies that its management believes could make a significant difference to patients and society worldwide. PharmaHub's corporate goal is to create maximum value from existing intellectual properties and technologies of its global partners by utilizing its broad-base of knowledge, understanding and resource allocation ability in the pharmaceutical and healthcare industries.

The FDA-approved version of this "magic bullet" cancer therapy has already improved the quality of life and offered longer life expectancy with minimum side effects for many patients suffering from inoperable liver cancer in the United States. The procedure is now used routinely in more than 43 clinical centers in 27 states, and was recently approved for coverage by two of the largest health insurers in the United States.  The therapy combats tumors in patients with hepatocellular carcinoma (HCC), commonly known as primary liver cancer, who cannot be treated with surgery, and are awaiting an organ transplant.

As the exclusive distributor in the Greater China Region, Singapore, Malaysia and Bangladesh of this new form of liver cancer treatment, PharmaHub believes that the therapy offers a solution to the problem of malignant liver cancer in Southeast Asia where approximately three-quarters of the cases of liver cancer worldwide are found. China, alone, has the highest number of liver cancer patients worldwide, approximately one-half of the world HCC population, with more than 350,000 new cases diagnosed each year, a number that is expected by Management to continue to rise in the coming years. As projected by IMS Health, China will become the world's third-largest pharmaceutical market by 2011, growing by more than 20% annually. Oncology is among the top five therapy classes in China, which recorded a staggering 27% compound annual growth rate ("CAGR") from 2005-2009 and is poised to achieve similar gains through 2015.

Richard Lui, CEO of PharmaHub stated, "We are thrilled with this opportunity to take a leadership role in introducing this type of radioembolization treatment for inoperable liver cancer in China and Southeast Asia. This therapy is a pioneering alternative to surgery, chemotherapy and other radiation therapies in current usage. Overall, the treatment can cause fewer and milder side effects than other current treatments and offers the convenience of outpatient therapy at a significantly lower price than the more conventional treatments."

"PharmaHub plans to immediately set up clinical studies in China to test wider applications of the medical technology, not only for liver but other cancers, then move to commercialization of the procedure in a cost-effective and reliable manner throughout China," stated Mr. Lui.   "We also foresee the potential medical application and commercial growth of this technology in other areas, including radiation synovectomy of arthritis joints."  

Dr. Handy Williamson, Vice Provost for International Programs at the University of Missouri-Columbia (MU) states "PharmaHub has presented a significant opportunity for some of MU's cutting edge innovations to be introduced into the arena of life saving application. Bringing good innovations into the marketplace is a strong aspiration shared by MU and other leading research universities across the US. In this instance our intuitional relationships in Asia are on the verge of bearing fruits."

"This is just the beginning," concluded Mr. Lui. "PharmaHub's goal is to become a worldwide leader in technology transfer. Our game plan is to rapidly acquire relevant proprietary technologies developed by leading research institutions, like MU. The 'PharmaHub Advantage' is that we have the experience to take a leadership role in leading our global partners towards efficiency and effectiveness."About PharmaHub:China PharmaHub Corp. is engaged in the business of licensing, developing and the commercialization of pharmaceutical and healthcare products and technologies between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, with initial emphasis in the United States and Europe. Management believes that PharmaHub brings a unique wealth of resources to assist scientists and companies in bringing their ideas to reality.  PharmaHub's corporate headquarters are located in California, with offices in Boston and China. For more information visit www.chnpharmahub.com .Contact:Monica DingChief Financial OfficerTel: (909) 843-6388   Cel: (626) 589-5136 Email: ir@chnpharmahub.com Forward-Looking StatementsThis press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein.


'/>"/>
SOURCE China PharmaHub Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
2. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
3. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
5. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
6. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
7. UPDATE: FDA Issues 22 Warning Letters to Web site Operators
8. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
9. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
10. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
11. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
Breaking Medicine Technology:
(Date:2/14/2016)... ... February 14, 2016 , ... ... of Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by ... of Life! Healthy Living with Heart Failure will kick-off February 14 and includes ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... In ... states that vein visualization technology should be used to ensure patient safety when ... world, the INS Standards mandate the use of vein visualization technology in patients ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
Breaking Medicine News(10 mins):